Drug · DIN 02418398 · Radiopharmaceutical
XOFIGO
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 26, 2018; first marketed May 8, 2014.
- Drug Identification Number (DIN)
- 02418398
- Company (DIN owner)
- Bayer Inc.Elkhart, Indiana, United States
- Schedule
- Schedule c
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- RADIUM (223Ra) DICHLORIDE V10XX03
- Class
- Radiopharmaceutical
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RADIUM RA-223 DICHLORIDE | 1100 KBq | ML |
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “xofigo”. A notice may cover another product or only some lots: read it to see what it covers.
- XOFIGO® (radium Ra 223 dichloride) - Increased Incidence of Fractures and Trend for Increased Deaths with XOFIGO used in combination with abiraterone and prednisone/prednisoloneNovember 8, 2018 · Biologic or vaccine · Product safety